These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 29926358)
1. Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions? Stevens JW Pharmacoeconomics; 2018 Oct; 36(10):1135-1141. PubMed ID: 29926358 [TBL] [Abstract][Full Text] [Related]
2. Decision aids for people facing health treatment or screening decisions. O'Connor AM; Bennett CL; Stacey D; Barry M; Col NF; Eden KB; Entwistle VA; Fiset V; Holmes-Rovner M; Khangura S; Llewellyn-Thomas H; Rovner D Cochrane Database Syst Rev; 2009 Jul; (3):CD001431. PubMed ID: 19588325 [TBL] [Abstract][Full Text] [Related]
3. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021 [TBL] [Abstract][Full Text] [Related]
4. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration. Backhouse ME Pharmacoeconomics; 2002; 20(15):1061-77. PubMed ID: 12456201 [TBL] [Abstract][Full Text] [Related]
5. [Decision analytic modeling and their impact on health care decision making]. Inotai A; Kaló Z; Mészáros A Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636 [TBL] [Abstract][Full Text] [Related]
6. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Cooper NJ; Sutton AJ; Abrams KR Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986 [TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762 [TBL] [Abstract][Full Text] [Related]
8. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Siebert U; Rochau U; Claxton K Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327 [TBL] [Abstract][Full Text] [Related]
9. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland. Schmitz S; McCullagh L; Adams R; Barry M; Walsh C Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245 [TBL] [Abstract][Full Text] [Related]
10. Oncology from an HTA and Health Economic Perspective. Francois C; Zhou J; Pochopien M; Achour L; Toumi M Recent Results Cancer Res; 2019; 213():25-38. PubMed ID: 30543005 [TBL] [Abstract][Full Text] [Related]
12. Good practice guidelines for the use of statistical regression models in economic evaluations. Kearns B; Ara R; Wailoo A; Manca A; Alava MH; Abrams K; Campbell M Pharmacoeconomics; 2013 Aug; 31(8):643-52. PubMed ID: 23807751 [TBL] [Abstract][Full Text] [Related]
13. Whither trial-based economic evaluation for health care decision making? Sculpher MJ; Claxton K; Drummond M; McCabe C Health Econ; 2006 Jul; 15(7):677-87. PubMed ID: 16491461 [TBL] [Abstract][Full Text] [Related]
14. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer. Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023 [TBL] [Abstract][Full Text] [Related]
15. Uncertainty in assessing value of oncology treatments. Mullins CD; Montgomery R; Tunis S Oncologist; 2010; 15 Suppl 1():58-64. PubMed ID: 20237219 [TBL] [Abstract][Full Text] [Related]
16. Presentation of economic evaluation results. Chaikledkaew U; Teerawattananon Y J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489 [TBL] [Abstract][Full Text] [Related]
17. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. Samsa GP; Reutter RA; Parmigiani G; Ancukiewicz M; Abrahamse P; Lipscomb J; Matchar DB J Clin Epidemiol; 1999 Mar; 52(3):259-71. PubMed ID: 10210244 [TBL] [Abstract][Full Text] [Related]
19. Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. de Groot S; Rijnsburger AJ; Versteegh MM; Heymans JM; Kleijnen S; Redekop WK; Verstijnen IM BMJ Open; 2015 Jul; 5(7):e007241. PubMed ID: 26220869 [TBL] [Abstract][Full Text] [Related]
20. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Doshi JA; Glick HA; Polsky D Value Health; 2006; 9(5):334-40. PubMed ID: 16961551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]